Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504123 · ClinicalTrials.gov registry record · Phase 2
MMP-9 Inhibition for Recalcitrant Wet AMD
A Phase 2 study, sponsored by University of Iowa.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT04504123 is a Phase 2 study that is actively recruiting participants, run by University of Iowa. The registered enrollment target is 50 participants.
The verdict
NCT04504123, a Phase 2 study, is actively recruiting participants, sponsored by University of Iowa.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.
Interventions
- DRUG Placebo
- DRUG Doxycycline Hyclate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504123
The ClinicalTrials.gov registry entry for NCT04504123 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04504123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504123 about?
NCT04504123 is a clinical study titled "MMP-9 Inhibition for Recalcitrant Wet AMD". Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90...
What is the current status of trial NCT04504123?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-11-04. Estimated completion is 2027-03-01.
What interventions are being tested in trial NCT04504123?
The interventions under investigation include: Placebo (DRUG), Doxycycline Hyclate (DRUG).
Who is sponsoring clinical trial NCT04504123?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.